References
- Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol 2019; 30: 863-70]. Ann Oncol 2018; 29(Suppl 4): iv192-237. doi: 10.1093/annonc/mdy275
- World Health Organization. International Agency for Research on Cancer (IARC). GLOBOCAN 2020. Cancer today. Lung. [internet]. [cited 2021 Feb 16]. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf
- Carcereny E, Morán T, Capdevila L, Cros S, Vilà L, de Los Llanos Gil M, et al. The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med 2015; 3: 1. doi: 10.1186/s40247-015-0013-z
- Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer 2019; 137: 113-22. doi: 10.1016/j.lungcan.2019.09.017
- Vansteenkiste J, Wauters E. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years. Ann Oncol 2018; 29(Suppl 1): i1-i2. doi: 10.1093/annonc/mdx724
- Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 2018; 29(Suppl 1): i10-i19. doi: 10.1093/annonc/mdx703
- Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, et al. Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance. Cancers 2019; 11: 923. doi: 10.3390/cancers11070923
- Mok TS, Wu Y-L, Ahn M-J, Kim HR, Ramalingam SS, Shepherd FA, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629-40. doi: 10.1056/NEJMoa1612674
- Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113-25. doi: 10.1056/NEJMoa1713137
- Cufer T, Ciuleanu TE, Berzinec P, Galffy G, Jakopovic M, Jassem J, et al. Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: a Central European Cooperative Oncology Group analysis. Oncologist 2020; 25: e598-601. doi: 10.1634/theoncologist.2019-0523
- Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer 2018; 18: 269. doi: 10.1186/s12885-018-4023-4
- Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. doi: 10.1515/raon-2017-0008
- Zwitter M, Čufer T, Vrankar M, Kern I, Štupnik T, Rozman A, et al. Lung cancer in Slovenia. J Thorac Oncol 2019; 14: 1327-31. doi: 10.1016/j. jtho.2019.02.025
- Zanetti R, Sacchetto L, Coebergh JW, Rosso S. To accelerate cancer prevention in Europe: challenges for cancer registries. Eur J Cancer 2018; 104: 151-9. doi: 10.1016/j.ejca.2018.09.001
- Thunissen E, Weynand B, Udovicic-Gagula D, Brcic L, Szolkowska M, Hofman P, et al. Lung cancer biomarker testing: perspective from Europe. Transl Lung Cancer Res 2020; 9: 887-897. doi: 10.21037/tlcr.2020.04.07
- Janzic U, Knez L, Janzic A, Cufer T. Time to access to novel anticancer drugs and the correlation with ESMO-magnitude of clinical benefit scale in Slovenia. Expert Rev Pharmacoecon Outcomes Res 2019; 19: 717-23. doi: 10.1080/14737167.2019.1702879
- Hirsh V, Singh J. Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: clinical benefits and cost-effectiveness. Am J Health Syst Pharm 2020; 77: 1466-76. doi: 10.1093/ ajhp/zxaa197
- Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol 2017; 28: 2715-24. doi: 10.1093/ annonc/mdx404
- Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C. Epidemiological characteristics, EGFR status and management patterns of advanced non-small cell lung cancer patients: the Greek REASON observational registry study. Anticancer Res 2018; 38: 3735-44. doi: 10.21873/anticanres.12654
- Schuette W, Schirmacher P, Eberhardt WEE, Dietel M, Zirrgiebel U, Muehlenhoff L, et al. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study. BMC Cancer 2018; 18: 135. doi: 10.1186/s12885-018-4032-3
- Reale ML, Chiari R, Tiseo M, Vitiello F, Barbieri F, Cortinovis D, et al. Be-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer 2020; 140: 71-9. doi: 10.1016/j. lungcan.2019.12.006
- Pluzanski A, Krzakowski M, Kowalski D, Dziadziuszko R. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. ESMO Open 2020; 5: e001011. doi: 10.1136/ esmoopen-2020-001011
- Pereira I, Gaspar C, Pina M, Azevedo I, Rodrigues A. Real-world T790M mutation frequency and impact of rebiopsy in patients with EGFR-mutated advanced non-small cell lung cancer. Cureus 2020; 12: e12128. doi: 10.7759/ cureus.12128
- Gijtenbeek RGP, Damhuis RAM, Groen HJM, van der Wekken AJ, van Geffen WH. Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer. Clin Lung Cancer 2020; 21: e647-53. doi: 10.1016/j. cllc.2020.05.019
- Chiang AC, Fernandes AW, Pavilack M, Wu JW, Laliberté F, Duh MS, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer 2020; 20: 356. doi: 10.1186/s12885-020-06826-0
- Cuppens K, Lodewyckx L, Demedts I, Decoster L, Colinet B, Deschepper K, et al. Real-world treatment patterns, epidermal growth factor receptor (EGFR) testing and outcomes in EGFR-mutated advanced non-small cell lung cancer patients in Belgium: results from the REVEAL study. Drugs Real World Outcomes 2021; 8: 141-52. doi: 10.1007/s40801-021-00243-w
- Addeo A, Hochmair M, Janzic U, Dudnik E, Charpidou A, Płużański A, et al. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Ther Adv Med Oncol 2021; 13: 1-11. doi: 10.1177/17588359211059874
- Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, et al. Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open 2017; 2: e000214. doi: 10.1136/esmoopen-2017-000214
- Unk M, Mohorčič K, Osrajnik I, Čufer T. Lung cancer – Slovenian clinical practice guidelines in systemic treatment 2017. [Slovenian]. Onkologija 2017; 21: 52-62.
- Minari R, Mazzaschi G, Bordi P, Gnetti L, Alberti G, Altimari A, et al. Detection of EGFR-activating and T790M mutations using liquid biopsy in patients with EGFR-mutated non-small-cell lung cancer whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors: a multicenter real-life retrospective study. Clin Lung Cancer 2020; 21: e464-73. doi: 10.1016/j.cllc.2020.02.021
- Dal Maso A, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, et al. Clinical features and progression pattern of acquired T790M-positive compared with T790M-negative EGFR mutant non-small-cell lung cancer: catching tumor and clinical heterogeneity over time through liquid biopsy. Clin Lung Cancer 2020; 21: 1-14.e3. doi: 10.1016/j.cllc.2019.07.009
- Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. Front Oncol 2014; 4: 248. doi: 10.3389/fonc.2014.00248
- Page S, Milner-Watts C, Perna M, Janzic U, Vidal N, Kaudeer N, et al. Systemic treatment of brain metastases in non-small cell lung cancer. Eur J Cancer 2020; 132: 187-98. doi: 10.1016/j.ejca.2020.03.006
- Li L, Luo S, Lin H, Yang H, Chen H, Liao Z, et al. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. J Thorac Dis 2017; 9: 2510-20. doi: 10.21037/ jtd.2017.07.57
- Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol 2014; 48: 173-83. doi: 10.2478/raon-2014-0016
- Shinde A, Akhavan D, Sedrak M, Glaser S, Amini A. Shifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases. CNS Oncol 2019; 8: CNS27. doi: 10.2217/cns-2018-0016
- Roeper J, Kurz S, Grohé C, Griesinger F. Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. Future Oncol 2021; 17: 471-86. doi: 10.2217/fon-2020-0854
- Nadler E, Pavilack M, Espirito JL, Clark J, Fernandes A. Observational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR-tyrosine kinase inhibitors. Adv Ther 2020; 37: 946-54. doi: 10.1007/ s12325-020-01221-4
- Wang F, Li C, Wu Q, Lu H. EGFR exon 20 insertion mutations in non-small cell lung cancer. Transl Cancer Res 2020; 9: 2982-91. doi: 10.21037/ tcr.2020.03.10
- Remon J, Hendriks LEL, Cardona AF, Besse B. EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins. Cancer Treat Rev 2020; 90: 102105. doi: 10.1016/j.ctrv.2020.102105
- Dent RAG, Cole P. In vitro maturation of monocytes in squamous carcinoma of the lung. Br J Cancer 1981; 43: 486-95. doi: 10.1038/bjc.1981.71
- Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919. doi: 10.1136/bmj.i4919
- Chapman S, Nakielny R. A guide to radiological procedures. London: Bailliere Tindall; 1986.
- Evans R, Alexander P. Mechanisms of extracellular killing of nucleated mammalian cells by macrophages. In: Nelson DS, editor. Immunobiology of macrophage. New York: Academic Press; 1976. p. 45-74.